Breaking News

Financial Report: Anacor Pharmaceuticals

March 15, 2013

Development milestone boost results

Anacor Pharmaceuticals
4Q Revenues: $3.3 million (+27%)

4Q Loss: $12.5 million (loss of $14.5 million 4Q11)

FY Revenues: $10.7 million (revenues were $20.3 million FY11)

FY Loss: $56.1 million (loss of $47.9 million FY11)

Comments: Growth in the quarter was primarily due to the $1.0 million development milestone under a collaboration with Lilly, partially offset by decreases in revenues from our neglected diseases programs. R&D expenses were down 14% to $12.0 million in the quarter.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.